During the last session, Nutex Health Inc (NASDAQ:NUTX)’s traded shares were 0.15 million, with the beta value of the company hitting -0.91. At the end of the trading day, the stock’s price was $149.00, reflecting an intraday gain of 8.85% or $12.11. The 52-week high for the NUTX share is $142.58, that puts it up 4.31 from that peak though still a striking 97.21% gain since the share price plummeted to a 52-week low of $4.16. The company’s market capitalization is $823.74M, and the average intraday trading volume over the past 10 days was 0.17 million shares, and the average trade volume was 71.71K shares over the past three months.
Nutex Health Inc (NUTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. NUTX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 3.9.
Nutex Health Inc (NASDAQ:NUTX) trade information
Nutex Health Inc (NUTX) registered a 8.85% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.85% in intraday trading to $149.00, hitting a weekly high. The stock’s 5-day price performance is 29.85%, and it has moved by 187.92% in 30 days. Based on these gigs, the overall price performance for the year is 2059.42%. The short interest in Nutex Health Inc (NASDAQ:NUTX) is 84591.0 shares and it means that shorts have 1.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $45, which implies a decrease of -231.11% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $45 and $45 respectively. As a result, NUTX is trading at a premium of 69.8% off the target high and 69.8% off the low.
Nutex Health Inc (NUTX) estimates and forecasts
In the rating firms’ projections, revenue will increase 10.06% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 136.87M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 131.33M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 67.45M and 76.08M respectively. In this case, analysts expect current quarter sales to grow by 102.90% and then jump by 72.61% in the coming quarter.
While earnings are projected to return -6.97% in 2025.
NUTX Dividends
Nutex Health Inc is due to release its next quarterly earnings on 2025-Mar-30. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Nutex Health Inc (NASDAQ:NUTX)’s Major holders
Nutex Health Inc insiders own 38.42% of total outstanding shares while institutional holders control 16.65%, with the float percentage being 27.04%. WEALTHCOLLAB, LLC is the largest shareholder of the company, while 47.0 institutions own stock in it. As of 2024-06-30, the company held over 0.13 million shares (or 0.2614% of all shares), a total value of $12157.0 in shares.
The next largest institutional holding, with 976.0 shares, is of RHUMBLINE ADVISERS’s that is approximately 0.002% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $580.0.
Also, the Mutual Funds coming in first place with the largest holdings of Nutex Health Inc (NUTX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and American Century ETF Trust-Avantis U.S. Small Cap Value ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 68.57 shares. This amounts to just over 1.24 percent of the company’s overall shares, with a $10.22 million market value. The same data shows that the other fund manager holds slightly less at 61.35, or about 1.11% of the stock, which is worth about $9.14 million.
